title: IL-2-induced growth of CD8+ T cell prolymphocytic leukemia cells mediated by NF-kappaB induction and IL-2 receptor alpha expression.
abstract: The binding of interleukin-2 (IL-2) to its receptor on normal T cells induces nuclear expression of nuclear factor kappaB (NF-kappaB), activation of the IL-2 receptor (IL-2R) alpha chain gene, and cell proliferation. In the present study, the role of IL-2R signaling in the growth of CD8+ T cell prolymphocytic leukemia (T-PLL) cells has been investigated. Flow cytometry revealed that primary leukemia cells from a patient with CD8+ T-PLL expressed IL-2Ralpha and beta chains, and the cells showed a proliferative response and an increase in IL-2Ralpha expression on culture with exogeneous IL-2. Northern blot analysis failed to detect IL-2 mRNA, suggesting that IL-2 may act in a paracrine manner in vivo. Electrophoretic mobility-shift assays revealed that recombinant IL-2 increased NF-kappaB binding activity in nuclear extracts of the leukemia cells, and Northern blot analysis showed that IL-2 increased the abundance of mRNAs encoding the NF-kappaB components c-Rel and KBF1 in these cells. IL-2 binding analysis demonstrated that IL-2 markedly increased the number of low affinity IL-2Rs on the leukemia cells, without an effect on the number of high-affinity IL-2Rs. These results show that IL-2 is capable of inducing the nuclear expression of NF-kappaB in primary CD8+ T-PLL cells, and that this effect is mediated, at least in part, at a pretranslational level.
authors.affiliation: First Department of Internal Medicine, Kagoshima University, Sakuragaoka, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Arima
authors.forename: K
authors.initials: K
authors.lastname: Matsushita
authors.forename: Y
authors.initials: Y
authors.lastname: Suruga
authors.forename: H
authors.initials: H
authors.lastname: Ohtsubo
authors.forename: H
authors.initials: H
authors.lastname: Fujiwara
authors.forename: S
authors.initials: S
authors.lastname: Hidaka
authors.forename: K
authors.initials: K
authors.lastname: Arimura
authors.forename: T
authors.initials: T
authors.lastname: Kukita
authors.forename: K
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: J
authors.initials: J
authors.lastname: Fukumori
authors.forename: H
authors.initials: H
authors.lastname: Tanaka
mesh_terms: D015152:Blotting, Northern; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects; D005434:Flow Cytometry; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis / Q000378:metabolism / Q000494:pharmacology*; D015463:Leukemia, Prolymphocytic / Q000378:metabolism* / Q000473:pathology*; D015458:Leukemia, T-Cell / Q000378:metabolism* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D016328:NF-kappa B / Q000096:biosynthesis* / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D020569:Proto-Oncogene Proteins c-rel; D012333:RNA, Messenger / Q000378:metabolism; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis* / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D007376:Interleukin-2; D016328:NF-kappa B; D011518:Proto-Oncogene Proteins; D020569:Proto-Oncogene Proteins c-rel; D012333:RNA, Messenger; D015375:Receptors, Interleukin-2